Seroatlas · Human Serome Atlas

HTR1F

5-hydroxytryptamine receptor 1F

Also known as: 5-HT1F, 5HT1F_HUMAN, HTR1EL

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P30939
Gene: HTR1F
Ensembl: ENSG00000179097
Chromosome: 3
Canonical length: 366 aa
Protein class: FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins

OverviewNCBI Gene

Enables Gi/o-coupled serotonin receptor activity; serotonin binding activity; and serotonin receptor activity. Involved in adenylate cyclase-inhibiting serotonin receptor signaling pathway. Located in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

366 residues, UniProt reviewed canonical sequence.

>P30939|HTR1F
     1  MDFLNSSDQN LTSEELLNRM PSKILVSLTL SGLALMTTTI NSLVIAAIIV TRKLHHPANY
    61  LICSLAVTDF LVAVLVMPFS IVYIVRESWI MGQVVCDIWL SVDITCCTCS ILHLSAIALD
   121  RYRAITDAVE YARKRTPKHA GIMITIVWII SVFISMPPLF WRHQGTSRDD ECIIKHDHIV
   181  STIYSTFGAF YIPLALILIL YYKIYRAAKT LYHKRQASRI AKEEVNGQVL LESGEKSTKS
   241  VSTSYVLEKS LSDPSTDFDK IHSTVRSLRS EFKHEKSWRR QKISGTRERK AATTLGLILG
   301  AFVICWLPFF VKELVVNVCD KCKISEEMSN FLAWLGYLNS LINPLIYTIF NEDFKKAFQK
   361  LVRCRC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against HTR1F can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 3.3 nTPM

Expression across tissuesHPA

Tissue

retina: 3.3 nTPM
placenta: 1.7 nTPM
adipose tissue: 0.6 nTPM
bone marrow: 0.6 nTPM
spleen: 0.6 nTPM
cerebral cortex: 0.5 nTPM

Single-cell type

hematopoietic stem cells: 3,590 nCPM
megakaryocyte-erythroid progenitors: 1,766 nCPM
lactotrophs: 1,048 nCPM
megakaryocyte progenitors: 693 nCPM
thymocytes: 342 nCPM
pericytes: 315 nCPM

Immune cell

basophil: 0.7 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 6.5 nTPM
white matter: 4.7 nTPM
midbrain: 3.8 nTPM
basal ganglia: 2.9 nTPM
amygdala: 2.3 nTPM
hippocampal formation: 1.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.1
gnomAD pLI: 0
gnomAD missense Z: 1.03
DepMap mean gene effect: 0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

G protein-coupled receptor, rhodopsin-like
5-hydroxytryptamine receptor family
GPCR, rhodopsin-like, 7TM
7 transmembrane receptor (rhodopsin family)
5-Hydroxytryptamine 1F receptor

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads HTR1F as an antibody target. Whether an autoantibody or antibody against HTR1F could matter depends on whether native HTR1F is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

HTR1F is annotated at the cell surface, where native HTR1F is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label HTR1F as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...